A Phase 1, open-label, single-center study to determine pharmacokinetics (PK) and safety of ODV in participants who were Japanese or White
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Obeldesivir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 23 Jan 2025 New trial record